KH Feelux Co., Ltd - 30 Apr 2025 Form 3 Insider Report for Liminatus Pharma, Inc. (LIMN)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
27 Jun 2025, 18:16:11 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
KH Feelux Co., Ltd, /s/ Bosung Bae, CEO

Key filing fact

KH Feelux Co., Ltd filed Form 3 for Liminatus Pharma, Inc. (LIMN) on 27 Jun 2025.

Key facts

  • This page summarizes KH Feelux Co., Ltd's Form 3 filing for Liminatus Pharma, Inc. (LIMN).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 27 Jun 2025, 18:16.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002068957 Primary reporting owner

KH Feelux Co., Ltd

Relationship
10%+ Owner
Address
J BUILDING, 32, EONJU-RO 71-GIL, GANGNAM-GU, SEOUL, KOREA, REPUBLIC OF
Signature
KH Feelux Co., Ltd, /s/ Bosung Bae, CEO
Signature date
27 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LIMN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
4,000,000
Date
30 Apr 2025
Ownership
Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .